FDA mulls compounding for peptides previously flagged over safety risks BioSpace The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law Peptide Therapy in Boise Specialized Treatment for First Responders Blueline Wellness Mitigating Risks of Compounded Drugs Through Surveillance FDA